KEYTRUDA is the first immunotherapy approved in the EU for the first-line treatment of this patient population
Hospital joins with Intuitive to install da Vinci systems to support enhanced healthcare delivery and patient outcomes across India
Investigational cellular therapy, bemdaneprocel (BRT-DA01), was well tolerated with no major safety issues in all 12 participants in low dose and high dose cohorts through one year / At one-year
First PARP inhibitor approved in Japan to demonstrate clinically meaningful benefits in combination with a new hormonal agent
India will account for about 18% of the Asia-Pacific (APAC) MRI systems market in 2023
NIH’s candidate is based on the Adenovirus 4 backbone, largely used as a vector candidate in HIV and influenza vaccine clinical trials
Combating the prevalent stigma against TB in the society, India has been committed to providing, enabling and patient-centric support to all, individuals suffering from TB
The survey findings for Delhi-NCR revealed that speech sound disorders exhibit higher prevalence rates in the 6-12 years age group
ELREXFIO’s label contains a boxed warning for cytokine release syndrome and neurologic toxicity
Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy
Subscribe To Our Newsletter & Stay Updated
